Eli Lilly, Boehringer Ingelheim announce linagliptin trial results
INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.
Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.
After 24 weeks, the companies said, patients with poorly controlled blood sugar showed HbA1C reductions of 3.7%. Most patients tolerated the drug well, with 9% experiencing adverse side effects and 1.5% reporting abnormally low blood sugar, also known as hypoglycemia.
"Many patients with high HbA1C levels require more than metformin alone to reach their blood glucose targets," Boehringer Ingelheim corporate SVP medicine Klaus Dugi said. "Linagliptin can support patients with Type 2 diabetes to effectively manage their condition in order [to] reach their blood-glucose targets."
In another study, patients who could not take metformin were given linagliptin or the generic drug glimepiride in a 34-week extension phase of a one-year trial. HbA1C levels in linagliptin patients remained stable between week 18 and week 52. Glimepiride showed similar levels of efficacy, but linagliptin produced fewer adverse side effects, the companies said.
NACDS supports anticounterfeiting legislation
ALEXANDRIA, Va. — New legislation proposed in the Senate would strengthen penalties against people who traffic in counterfeit medications.
Introduced by Sen. Patrick Leahy, D-Vt., S. 1886, the Counterfeit Drug Penalty Enhancement Act of 2011, would harshen laws against producing, buying or selling counterfeit drugs. The bill has received support from the chain retail pharmacy lobby.
"[The National Association of Chain Drug Stores] and the chain pharmacy industry applaud your leadership in taking steps to protect American consumers by advocating for stricter sentences for criminals in the counterfeit medicine business," a letter the organization sent to Sen. Leahy read. "Presently, the federal penalty for a counterfeiting crime is typically three years. We believe that stronger deterrents, as provided in your legislation, are more appropriate for these potentially deadly crimes involving counterfeit medicine."
GPhA appoints new executive
WASHINGTON — The Generic Pharmaceutical Association has appointed a new executive who will help guide the organization’s newly created research and education institute.
The organization announced Thursday the appointment of Ahaviah Glaser as VP policy and strategic alliances. Glaser previously was a member of AARP’s government affairs team.
"Through GPhA and the newly created Affordable Medicines Research Institute, Havi will help educate both the public at large and policy makers around the world about the safety and efficacy of generic medicines, as well as the extraordinary healthcare savings that generics provide," GPhA president and CEO Ralph Neas said.
"In a time when budget challenges and healthcare costs are colliding as never before, not only for governments but for families, Havi’s job will be to help shepherd research, education and outreach efforts to ensure that all Americans fully understand that generic pharmaceuticals reduce healthcare costs while maintaining the high-quality standard of care that they rightly expect," Neas added.